TruAlt Bioenergy Q4FY26 Results: Revenue Declines 7.85% YoY to ₹1813.96 Cr
TruAlt Bioenergy reported a 7.85% year-on-year decline in consolidated total income to ₹1813.96 crore for FY26. EBITDA fell 1.85% to ₹362.35 crore. The company is advancing its ₹2250 crore SAF project and expanding its CBG business through JVs with GAIL and Sumitomo. A pending 15 crore litre ethanol allocation has an estimated revenue potential of ₹1062 crore.
The decline in revenue and EBITDA, coupled with delays in a significant ethanol allocation, indicates a negative short-term impact. However, ongoing strategic initiatives in SAF and CBG, along with the potential recovery from the pending allocation, suggest a medium-term impact.
The company's financial results show a decline in total income and EBITDA for the year ended March 31, 2026, compared to the previous year, primarily due to reduced ethanol offtake and execution delays.
TruAlt Bioenergy Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a total income of ₹1813.96 crore for the year ended March 31, 2026, a decrease of 7.85% compared to ₹1968.53 crore in the previous year. EBITDA also saw a decline of 1.85% to ₹362.35 crore from ₹369.17 crore.
The company's performance was impacted by reduced offtake of ethanol by Oil Marketing Companies (OMCs) and delays in the execution of a pending 15 crore litre allocation, which has an estimated revenue potential of ₹1062 crore. This pending allocation is expected to contribute positively to the company's future growth and operational recovery.
TruAlt Bioenergy is strategically progressing its Sustainable Aviation Fuel (SAF) project, with an estimated investment of ₹2250 crore. The project is in the FEED stage with Honeywell UOP, and the company is in discussions with the Government of Andhra Pradesh for incentives. Potential viability gap funding of approximately ₹150 crore under the PM JI-VAN Yojana scheme is expected, with commissioning targeted within 24 to 30 months.
The company is also strengthening its Compressed Biogas (CBG) segment through joint ventures with GAIL (India) Limited and Sumitomo Corporation. Construction is underway for 4 CBG plants under TruAlt Gas, and land has been identified for 6 additional plants under Leafiniti Bioenergy, with construction expected to commence soon. The CBG-CGD synchronisation framework and a Union Budget 2026-27 exemption on central excise duty for blended CNG are expected to bolster the CBG segment.
The retail fuel network currently has 7 operational outlets, with 4 more under construction. The company has shortlisted 76 additional locations for future expansion.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.